Description
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
Please contact Anayansi Miloud to learn more about the eligibility criteria for this trial. Please use the contact form on the right side.
Sites
-
California
- USC/Kenneth Norris Comprehensive Cancer Center Onc Dept, Los Angeles, California, 90033
- University of California at Los Angeles UCLA SC, Los Angeles, California, 90095
- University of California San Francisco Oncology, San Francisco, California, 94101
-
Illinois
- NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Onc Dept, Chicago, Illinois, 60611
-
Germany
- Novartis Investigative Site, Heidelberg, 69120
-
Taiwan
- Novartis Investigative Site, Tainan, 70403
-
France
- Novartis Investigative Site, Rennes Cedex, 35062
Powered by
SC CTSI